Scott Ribich

Scott Ribich has a significant amount of work experience in the pharmaceutical and medical research field. Scott is currently working as the Vice President, Head of Discovery Biology at Blueprint Medicines since April 2022. Scott has also held senior leadership positions at Accent Therapeutics, Inc. as the Senior Vice President of Biology from January 2022 to March 2022, and as the Vice President of Biology from October 2017 to January 2022. Previously, they worked at Epizyme as the Director, Biological Sciences from March 2016 to September 2017, and in various roles such as Associate Director, Principal Scientist, and Senior Scientist in the Biological Sciences department from 2011 to 2016. Scott has also worked as a Senior Scientist and Scientist in the Department of Cell Biology at Sirtris Pharmaceuticals from 2008 to 2011. Scott started their career as a Postdoctoral Research Fellow at Brigham and Women's Hospital and Harvard Medical School from 2006 to 2008 and as a Postdoctoral Fellow at Harvard University from 2005 to 2006. Scott's extensive academic background includes being a Graduate Student at Harvard University from 1999 to 2005, where they conducted research on the transcriptional regulation of the alpha-Protocadherin gene cluster. Scott also worked as a Research Student at Millennium Pharmaceuticals in 1996.

Scott Ribich received their primary education at Belmont Hill School from 1989 to 1994. Scott then pursued higher education at Massachusetts Institute of Technology from 1994 to 1998, earning a Bachelor of Science degree in Biology. Scott furthered their studies at Harvard University from 1999 to 2005, obtaining a Ph.D. in Biochemistry.